Exemestane Plus Ovarian Suppression Best in Early ILC

New data add to the body of evidence favoring the aromatase inhibitor therapy plus ovarian suppression over tamoxifen for premenopausal women with early invasive lobular carcinoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/exemestane-plus-ovarian-suppression-best-early-invasive-2024a10009tv?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost